Sheaff Brock Investment Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 137.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,568 shares of the company's stock after purchasing an additional 25,203 shares during the quarter. Sheaff Brock Investment Advisors LLC's holdings in Johnson & Johnson were worth $7,061,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the business. International Assets Investment Management LLC lifted its stake in shares of Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company's stock valued at $559,832,000 after buying an additional 3,437,397 shares during the period. Marshall Wace LLP lifted its stake in shares of Johnson & Johnson by 506.9% during the 2nd quarter. Marshall Wace LLP now owns 3,884,962 shares of the company's stock worth $567,826,000 after purchasing an additional 3,244,862 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 16.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after purchasing an additional 3,139,499 shares during the last quarter. Ninety One UK Ltd grew its position in shares of Johnson & Johnson by 59.0% in the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company's stock valued at $980,579,000 after purchasing an additional 2,489,925 shares during the period. Finally, Swedbank AB acquired a new position in Johnson & Johnson in the first quarter valued at $331,178,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on JNJ shares. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, July 19th. Finally, Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $175.94.
Read Our Latest Report on JNJ
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock traded up $2.12 on Friday, reaching $153.99. 11,303,005 shares of the company were exchanged, compared to its average volume of 7,017,128. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $370.75 billion, a price-to-earnings ratio of 22.14, a P/E/G ratio of 2.72 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company's 50-day moving average is $161.56 and its two-hundred day moving average is $155.97.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the firm posted $2.66 earnings per share. The business's revenue was up 5.2% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.22%. Johnson & Johnson's dividend payout ratio is presently 71.78%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
